Mainz Biomed (NASDAQ:QUCY) Releases Quarterly Earnings Results

Mainz Biomed (NASDAQ:QUCY) posted its quarterly earnings results on Tuesday. The company reported ($0.02) EPS for the quarter, FiscalAI reports. The company had revenue of $0.13 million for the quarter.

Mainz Biomed Stock Performance

QUCY opened at $0.48 on Thursday. Mainz Biomed has a twelve month low of $0.40 and a twelve month high of $4.43.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Maxim Group lowered Mainz Biomed from a “strong-buy” rating to a “hold” rating in a report on Friday, March 6th. Weiss Ratings assumed coverage on Mainz Biomed in a research note on Thursday, March 12th. They issued a “sell (e+)” rating on the stock. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Reduce”.

Mainz Biomed Company Profile

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.